ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 666

Vitamin D Deficiency Is Associated with Increased Serum Cholesterol Among Patients with Systemic Lupus Erythematosus

Michelle Petri1, Daniel Goldman2 and Laurence S Magder3, 1Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: cholesterol and systemic lupus erythematosus (SLE), Vitamin D

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Vitamin D insufficiency/deficiency is common in SLE. In other populations, vitamin D has been associated with cardiovascular risk factors such as blood pressure and serum cholesterol. We assessed whether there was an association between serum vitamin D and total serum cholesterol in a large SLE cohort.

Methods: Serum 25-hydroxy vitamin D [25(OH)D] was measured at quarterly clinic visits in a large SLE cohort. 1358 different patients were observed from 1 to 40 visits (the median was 11). The patients were 92% female, 50% Caucasian, 41% African American. Age ranged from 17 to 89 years. When the 25(OH)D level was below 40 mg/ml, the patient was prescribed supplemental vitamin D, usually 50,000 IU weekly. We explored the association between serum vitamin D levels and serum cholesterol using longitudinal regression models.

Results: Levels of 25(OH)D below 50 ng/ml were associated with a higher mean cholesterol. There was a significantly negative linear relationship between vitamin D and mean cholesterol when 25(OH)D was below 50 ng/ml.

Table 1: Slope of Relationship Between 25(OH) Vitamin D and Mean Cholesterol Over Different Ranges of 25(OH) Vitamin D

Range of 25(OH) Vitamin D

Estimated slope (95% Confidence Interval)

Unadjusted

P-value

Adjusted

P-value

0-50 ng/ml

-0.37 (-0.42, -0.32)

<0.0001

-0.30 (-0.35, -0.24)

<0.0001

50+ ng/ml

-0.09 (-0.15, -0.02)

0.014

-0.11 (-0.18, -0.03)

0.0037

1 Adjusted for age, age-squared, sex, race, proportion of time on hydroxychloroquine use, corticosteroid use, BMI and systolic blood pressure.

Conclusion: We observed a decline in total cholesterol as vitamin D increased to the normal range. Vitamin D supplementation significantly reduced cholesterol, even after adjustment for hydroxychloroquine. Vitamin D, like hydroxychloroquine, has benefit beyond immunomodulation, in that it reduces multiple cardiovascular risk factors.


Disclosure: M. Petri, Anthera Inc, 5,GlaxoSmithKline, 5,EMD Serono, 5,Eli Lilly and Company, 5,Bristol Meyer Squibb, 5,Amgen, 5,United Rheumatology, 5,Global Academy, 5,Exagen, 2; D. Goldman, None; L. S. Magder, None.

To cite this abstract in AMA style:

Petri M, Goldman D, Magder LS. Vitamin D Deficiency Is Associated with Increased Serum Cholesterol Among Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/vitamin-d-deficiency-is-associated-with-increased-serum-cholesterol-among-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vitamin-d-deficiency-is-associated-with-increased-serum-cholesterol-among-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology